9/19 Vasculotide, An Angiopoietin 1 Mimetic, Protects Vascular Barrier Function In Acute Lung Injury

Wednesday, September 19th, 2018, 13:30-14:30 

Paul Van Slyke, Ph.D.
Chief Scientific Officer, Vasomune Therapeutics
Sunnybrook Research Institute

Vasculotide, An Angiopoietin 1 Mimetic, Protects Vascular Barrier Function In Acute Lung Injury

Tie2 is a receptor tyrosine kinase expressed primarily on endothelial cells throughout the body. Constitutive activation of this receptor, through engagement with its cognate ligand Angiopoietin 1, is critical to the maintenance of normal vascular barrier function. Dysregulation of the Tie2 pathway has been widely implicated in several critical care indications marked by vascular leak. As such, modulation of the Tie2 pathway has become a major target of interest for the pharmaceutical industry.

Vasomune Therapeutics, a private biotechnology company based in Toronto, Canada has recently entered into a Co-Development Agreement with AnGes, Inc.  (Osaka) to develop Vasculotide, an Angiopoietin 1 mimetic, for the treatment of acute respiratory distress syndrome (ARDS). The concept for Vasculotide as well as preclinical proof-of-concept data derived from three different models of ARDS will be discussed.